Literature DB >> 12740957

Longitudinal study of tuberculosis outcomes among immunologically naive Aché natives of Paraguay.

A Magdalena Hurtado1, Kim R Hill, Wilhelm Rosenblatt, Jacquelyn Bender, Tom Scharmen.   

Abstract

This study documents the course of a tuberculosis epidemic in an immunologically naive group of South American Indians within fewer than 20 years after first sustained contact with outsiders. Groups of Northern Aché (ah-CHAY) of eastern Paraguay were contacted and settled on reservations between 1971-1979. Not surprisingly, the Aché are very susceptible to tuberculosis, and the epidemiological characteristics of the disease are quite different from those of populations that have had tuberculosis for centuries. Within 6 years of the first detected case of tuberculosis among the Aché, the prevalence rate of active tuberculosis cases reached 18.2%, and of infected cases among adults, 64.6%, some of the highest rates ever reported for any human group. Remarkably, males and females are equally likely to have been diagnosed with active tuberculosis, Aché children between birth and 5 years of age are least vulnerable to tuberculosis, high nutritional and socioeconomic status do not decrease the risk of disease or infection, and children immunized with BCG are less responsive to tuberculin challenge than are other children. Moreover, similar to the Yanomamö, but unlike populations of European or African descent, a high percentage of Aché with active disease test negative on tuberculin challenge tests (purified protein derivative; PPD). These differences may be due to a high prevalence of diminished cell-mediated immunity, and T-helper 2 dominance. We also hypothesize that these immunological characteristics, low genetic diversity, hostile intergroup interactions, and behavioral noncompliance to treatment protocols together contribute to the high rates of active disease observed. Existing tuberculosis control programs are poorly equipped to handle the impact of these causal complexities on the course of recent tuberculosis epidemics that have quickly spread throughout native communities of Latin America during the last decade. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740957     DOI: 10.1002/ajpa.10228

Source DB:  PubMed          Journal:  Am J Phys Anthropol        ISSN: 0002-9483            Impact factor:   2.868


  6 in total

Review 1.  Burden of tuberculosis in indigenous peoples globally: a systematic review.

Authors:  D Tollefson; E Bloss; A Fanning; J T Redd; K Barker; E McCray
Journal:  Int J Tuberc Lung Dis       Date:  2013-07-02       Impact factor: 2.373

2.  Population variation and differences in serum leptin independent of adiposity: a comparison of Ache Amerindian men of Paraguay and lean American male distance runners.

Authors:  Richard G Bribiescas; Matthew S Hickey
Journal:  Nutr Metab (Lond)       Date:  2006-08-30       Impact factor: 4.169

3.  Modeling the potential impact of host population survival on the evolution of M. tuberculosis latency.

Authors:  Nibiao Zheng; Christopher C Whalen; Andreas Handel
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

Review 4.  Genetic Resistance to Mycobacterium tuberculosis Infection and Disease.

Authors:  Marlo Möller; Craig J Kinnear; Marianna Orlova; Elouise E Kroon; Paul D van Helden; Erwin Schurr; Eileen G Hoal
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

5.  Tuberculosis incidence inequalities and its social determinants in Manaus from 2007 to 2016.

Authors:  Daniel Barros de Castro; Elvira Maria Godinho de Seixas Maciel; Megumi Sadahiro; Rosemary Costa Pinto; Bernardino Cláudio de Albuquerque; José Ueleres Braga
Journal:  Int J Equity Health       Date:  2018-12-29

6.  Genetic polymorphism and immune response to tuberculosis in indigenous populations: a brief review.

Authors:  Renata Maronna Praça Longhi; Verônica Marques Zembrzuski; Paulo Cesar Basta; Julio Croda
Journal:  Braz J Infect Dis       Date:  2013-05-09       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.